Article
Cardiac & Cardiovascular Systems
Einar Sjaastad Norden, Bard Andre Bendiksen, Henriette Andresen, Kaja Knudsen Bergo, Emil Knut Espe, Almira Hasic, Ida Marie Hauge-Iversen, Ioanni Veras, Rizwan I. Hussain, Ivar Sjaastad, Geir Christensen, Alessandro Cataliotti
Summary: This study found that in a HFpEF model, sacubitril/valsartan (sac/val) reduced hypertrophy and improved diastolic dysfunction compared to valsartan alone, independent of blood pressure. The observed anti-hypertrophic effects in preserved ejection fraction suggest the potential benefit of sac/val in hypertrophic remodeling and impaired diastolic function.
Article
Cardiac & Cardiovascular Systems
Safia Chatur, Brian L. Claggett, Finnian R. McCausland, Jean Rouleau, Michael R. Zile, Milton Packer, Marc A. Pfeffer, Martin Lefkowitz, John J. V. McMurray, Scott D. Solomon, Muthiah Vaduganathan
Summary: An investigation found that moderate estimated glomerular filtration rate decline when transitioning from RASi to sacubitril/valsartan is not consistently associated with adverse outcomes, and its long-term benefits are retained across a broad range of eGFR declines in heart failure patients.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2023)
Review
Pharmacology & Pharmacy
Nor Hidayah Mustafa, Juriyati Jalil, Satirah Zainalabidin, Mohammed S. M. Saleh, Ahmad Yusof Asmadi, Yusof Kamisah
Summary: Cardiovascular diseases are a significant clinical burden worldwide, and heart failure is a common disease resulting from uncontrolled hypertension. Sacubitril/valsartan, a new drug combination, has been approved for patients with heart failure, but its molecular mechanism of action in cardiac remodeling is still unclear.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Medicine, Research & Experimental
Dina Salem Abdelaziz Elshenawy, Nehal Mohammed Ramadan, Vivian Boshra Abdo, Rehab Hamdy Ashour
Summary: In a rat model of DCM induced by HFD/STZ, sacubitril/valsartan treatment showed better improvement in metabolic changes compared to valsartan alone. Additionally, sacubitril/valsartan effectively prevented diabetes-associated cardiac hypertrophy, QTc prolongation, and fibrosis. Furthermore, the combination decreased cardiac glycogen concentrations and induced the glycophagy process in the diabetic rats' hearts.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Article
Medicine, General & Internal
Federica Valli, Francesca Bursi, Gloria Santangelo, Filippo Toriello, Andrea Faggiano, Irene Rusconi, Anna Maria Vella, Stefano Carugo, Marco Guazzi
Summary: Sacubitril/Valsartan (S/V) has potential anti-remodeling effects and improves right ventricular (RV) coupling to the pulmonary circulation. This study found that 27.6% of HFrEF patients experienced left ventricular (LV) reverse remodeling and there was a significant improvement in RV function. These findings suggest a potential long-term reverse global remodeling effect of S/V and highlight a possible direct effect of the drug on the interaction between RV and pulmonary circulation.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Biochemistry & Molecular Biology
Pema Raj, Karen Sayfee, Mihir Parikh, Liping Yu, Jeffrey Wigle, Thomas Netticadan, Shelley Zieroth
Summary: The study showed that in MI-induced rats, treatment with resveratrol, sacubitril/valsartan, and valsartan significantly prevented cardiac remodeling and dysfunction. These treatments worked by reducing cardiac oxidative stress, inflammation, and fibrosis, promoting heart health.
Article
Cardiac & Cardiovascular Systems
Amil. M. M. Shah, Brian Claggett, Narayana Prasad, Guichu Li, Mayra Volquez, Karola Jering, Maja Cikes, Attila Kovacs, Wilfried Mullens, Jose C. Nicolau, Lars Kober, Peter Van der Meer, Pardeep. S. S. Jhund, Ghionul Ibram, Martin Lefkowitz, Yinong Zhou, Scott. D. D. Solomon, Marc A. Pfeffer
Summary: This study compared the effects of sacubitril/valsartan and ramipril on left ventricular function and adverse remodeling after acute myocardial infarction (AMI). The results showed that patients randomized to sacubitril/valsartan had better improvements in filling pressure, left ventricular volume changes, and other aspects compared to those randomized to ramipril.
Article
Biology
Alfonso Campanile, Valeria Visco, Stefania De Carlo, Germano Junior Ferruzzi, Costantino Mancusi, Carmine Izzo, Felice Mongiello, Paola Di Pietro, Nicola Virtuoso, Amelia Ravera, Domenico Bonadies, Carmine Vecchione, Michele Ciccarelli
Summary: This study compares the effects of Sac/Val and standard medical therapy on prognostically significant CPET parameters in HFrEF patients. After a median follow-up of 16 months, no significant differences were observed in peak VO2 and other CPET measures between Sac/Val and standard therapy.
Article
Biochemistry & Molecular Biology
Maura Brioschi, Yuri D'Alessandra, Massimo Mapelli, Irene Mattavelli, Elisabetta Salvioni, Sonia Eligini, Alice Mallia, Veronica Ricci, Erica Gianazza, Stefania Ghilardi, Piergiuseppe Agostoni, Cristina Banfi
Summary: Sacubitril/Valsartan, a combination drug for heart failure treatment, reduces the levels of miR-29b-3p, miR-221-3p, and miR-503-5p in the plasma of patients with stable HF. These miRNAs have potential roles in HFrEF pathophysiology.
Article
Medicine, General & Internal
Valentina Mantegazza, Valentina Volpato, Massimo Mapelli, Valentina Sassi, Elisabetta Salvioni, Irene Mattavelli, Gloria Tamborini, Piergiuseppe Agostoni, Mauro Pepi
Summary: This study evaluated the effects of S/V on HFrEF patients using 3D transthoracic echocardiography and found improvements in LV size and biventricular function in non-ischaemic patients, whereas only LV function improved in ischaemic patients, with no effect on RV function. Diastolic function and NT-proBNP significantly improved in both groups. The study highlights the different impacts of S/V on LV function between non-ischaemic and ischaemic patients.
Article
Cardiac & Cardiovascular Systems
Sean P. Murphy, Jonathan H. Ward, Ileana L. Pina, G. Michael Felker, Javed Butler, Alan S. Maisel, Xiangyi Meng, Margaret F. Prescott, Scott D. Solomon, James L. Januzzi
Summary: This study investigated the age differences in the effects of Sac/Val in heart failure patients. The results showed that after 12 months of treatment, Sac/Val significantly improved biomarkers, cardiac remodeling, and health status in patients of different age groups. However, older patients showed less reduction in NT-proBNP and smaller improvement in KCCQ-23 overall summary scores.
JACC-HEART FAILURE
(2022)
Review
Cardiac & Cardiovascular Systems
Roberto Pontremoli, Claudio Borghi, Pasquale Perrone Filardi
Summary: Chronic kidney disease is common in patients with chronic heart failure and increases mortality risk, but the novel medication sacubitril/valsartan not only provides renal benefits but also reduces cardiovascular mortality risk.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY
(2021)
Article
Cardiac & Cardiovascular Systems
Jawad H. Butt, Pooja Dewan, Pardeep S. Jhund, Inder S. Anand, Dan Atar, Junbo Ge, Akshay S. Desai, Luis E. Echeverria, Lars Kober, Carolyn S. P. Lam, Aldo P. Maggioni, Felipe Martinez, Milton Packer, Jean L. Rouleau, David Sim, Dirk J. Van Veldhuisen, Bojan Vrtovec, Faiez Zannad, Michael R. Zile, Jianjian Gong, Martin P. Lefkowitz, Adel R. Rizkala, Scott D. Solomon, John J. McMurray
Summary: This study investigated the efficacy of sacubitril/valsartan in heart failure patients according to their frailty status. The results showed that frail patients had a higher risk and worse outcomes compared to nonfrail patients. Sacubitril/valsartan seemed to have a greater reduction in the primary endpoint with increasing frailty, indicating that frail patients may derive more benefits from this treatment.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Yahe Xu, Mingjie Zhang, Yijun Chen, Xi Chen, Wenting Song, Limin Zhu, Liping Liu, Xiaolei Gong, Yuqi Zhang, Zhuoming Xu
Summary: Sacubitril/valsartan may be effective in pediatric HF patients, but its safety and clinical outcomes may vary depending on the etiology and anatomy of HF.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2023)
Article
Cardiac & Cardiovascular Systems
Massimo Volpe, Johann Bauersachs, Antoni Bayes-Genis, Javed Butler, Alain Cohen-Solal, Giovanna Gallo, Andrea Simone Deichl, Muhammad Shahzeb Khan, Allegra Battistoni, Burkert Pieske, Yoshihiko Saito, Shelley Zieroth
Summary: Current international guidelines recommend switching ACE-i or ARBs to sacubitril/valsartan (S/V) in stable outpatients affected by heart failure with reduced ejection fraction (HFrEF) who remain symptomatic despite being on optimal medical therapy. New data may support further clinical applications and benefits of S/V beyond ambulatory HFrEF patients, possibly also in HFmrEF patients. Additional clinical trial data are required to confirm the potential benefits of S/V in patients with mid-range or preserved EF, or in combination with sodium-glucose co-transporter 2 inhibitors or in post-myocardial infarction HF.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2021)